Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in Major Depression

European Neuropsychopharmacology

Volumn 18, Issue 10, 2008, Pages 751-759

  Domschke, Katharina ^a   Dannlowski, Udo ^a   Ohrmann, Patricia ^a   Lawford, Bruce ^b   Bauer, Jochen ^a   Kugel, Harald ^a   Heindel, Walter ^a   Young, Ross ^c   Morris, Phillip ^c   Arolt, Volker ^a   Deckert, Jürgen ^d   Suslow, Thomas ^a   Baune, Bernhard T ^a,e  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e JAMES COOK UNIVERSITY   (Australia)

Author keywords

Anxiety; CNR1; Depression; Endocannabinoid system; Pharmacogenetic; Treatment response

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CANNABINOID 1 RECEPTOR; CITALOPRAM; ESCITALOPRAM; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AMYGDALOID NUCLEUS; ANXIETY; ARTICLE; CNR1 GENE; COMORBIDITY; EMOTION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC VARIABILITY; GLOBUS PALLIDUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUROBIOLOGY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PUTAMEN; REWARD;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSIVE DISORDER, MAJOR; EMOTIONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXYGEN; PHARMACOGENETICS; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, CANNABINOID, CB1; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 49649102306     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.05.003     Document Type: Article

References (42)

1. Barrero F., Ampuero I., Morales B., et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J. 5 (2005) 135-141
2. Baune B.T., Hohoff C., Berger K., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33 (2008) 924-932
3. Bierut L., Heath A., Bucholz K., et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women?. Arch. Gen. Psychiatry 56 (1999) 557-563
4. Blair R. Facial expressions, their communicatory functions and neuro-cognitive substrates. Philos. Trans. R. Soc. Biol. Sci. 358 (2003) 561-572
5. Canli T., Cooney R., Goldin P., et al. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16 (2005) 1267-1270
6. Chakrabarti B., Kent L., Suckling J., et al. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur. j. neurosci. 23 (2006) 1944-1948
7. Dannlowski U., Ohrmann P., Bauer J., et al. Amygdala response predicts automatic negative evaluations for facial emotions. Psychiatr. Res. - Neuroimaging 154 (2007) 13-20
8. Dannlowski U., Ohrmann P., Bauer J., et al. Amygdala reactivity in major depression is associated with automatic negative bias for facial emotions and life-time hospitalization. J. Psychiatr. Neurosci. 32 (2007) 423-429
9. Dannlowski U., Ohrmann P., Bauer J., et al. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 33 (2008) 418-424
10. Degenhardt L., Hall W., and Lynskey M. Exploring the association between cannabis use and depression. Addiction 98 (2003) 1493-1504
11. Deldin P., Keller J., Gergen J., et al. Cognitive bias and emotion in neuropsychological models of depression. Cogn. Emot. 15 (2001) 787-802
12. Domschke K., Braun M., Ohrmann P., et al. Association of the functional-1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int. J. Neuropsychopharmacol. 9 (2006) 349-355
13. Domschke K., Hohoff C., Mortensen L.S., et al. Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008) 224-228
14. Duan J., Wainwright M., Comeron J., et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12 (2003) 205-216
15. Ekman P., and Friesen W. Pictures of Facial Affect (1976), Consulting Psychologists Press, Palo Alto, CA, USA
16. Fu C., Williams S., Brammer M., et al. Neural responses to happy facial expressions in major depression following antidepressant treatment. Am. J. Psychiatr. 164 (2007) 599-607
17. González S., Bisogno T., Wenger T., et al. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem. Biophys. Res. Commun. 270 (2000) 260-266
18. Gunning-Dixon F., Gur R., Perkins A., et al. Age-related differences in brain activation during emotional face processing. Neurobiol. Aging 24 (2003) 285-295
19. Gur R., Erwin R., Gur R., et al. Facial emotion discrimination, II: behavioral findings in depression. Psychiatr. Res. 42 (1992) 241-251
20. Haller J., Bakos N., Szirmay M., et al. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur. j. neurosci. 16 (2002) 1395-1398
21. Hill M., and Gorzalka B. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. Behav. pharmacol. 16 (2005) 333-352
22. Hill M., Ho W., Sinopoli K., et al. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31 (2006) 2591-2599
23. Hill M., Karacabeyli E., and Gorzalka B. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 32 (2007) 350-357
24. Kendler K., Gardner C., Neale M., et al. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes?. Psychol. Med. 31 (2001) 605-616
25. Kessler R., Stang P., Wittchen H., et al. Lifetime panic-depression comorbidity in the national comorbidity survey. Arch. Gen. Psychiatry 55 (1998) 801-808
26. Lawrence N., Williams A., Surguladze S., et al. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol. psychiatry 55 (2004) 578-587
27. Lynskey M., Glowinski A., Todorov A., et al. Major depressive disorder, suicidal ideation, and suicide attempt in twins discordant for cannabis dependence and early-onset cannabis use. Arch. Gen. Psychiatry 61 (2004) 1026-1032
28. Maldjian J., Laurienti P., Kraft R., et al. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19 (2003) 1233-1239
29. Martin M., Ledent C., Parmentier M., et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berlin) 159 (2002) 379-387
30. Nakazi M., Bauer U., Nickel T., et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg's arch. pharmacol. 361 (2000) 19-24
31. Oeth P., Beaulieu M., Park C., et al. iPLEX™ Assay: Increased Plexing Efficiency and Flexibility for MassARRAY System Through Single Base Primer Extension with Mass-Modified Terminators (2007). http://www.agrf.org.au/docstore/snp/iPlex.pdf http://www.agrf.org.au/docstore/snp/iPlex.pdf
32. Persad S., and Polivy J. Differences between depressed and nondepressed individuals in the recognition of and response to facial emotional cues. J. Abnorm. Psychol. 102 (1993) 358-368
33. Rottenberg J., Kasch K., Gross J., et al. Sadness and amusement reactivity differentially predict concurrent and prospective functioning in major depressive disorder. Emotion 2 (2002) 135-146
34. Roy-Byrne P., Stang P., Wittchen H., et al. Lifetime panic-depression comorbidity in the national comorbidity survey. Associations with symptoms, impairment, course and help-seeking. Br. J. Psychiatry 176 (2000) 229-235
35. Schmidt L., Samochowiec J., Finckh U., et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug alcohol depend. 65 (2002) 221-224
36. Suslow T., Junghanns K., and Arolt V. Detection of facial expressions of emotions in depression. Percept. mot. skills 92 (2001) 857-868
37. Suslow T., Dannlowski U., Lalee-Mentzel J., et al. Spatial processing of facial emotion in patients with unipolar depression: a longitudinal study. J. affect. disord. 83 (2004) 59-63
38. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (2002) 273-289
39. Weissman M., Bland R., Canino G., et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276 (1996) 293-299
40. Willeit M., Praschak-Rieder N., Neumeister A., et al. A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol. Psychiatry 8 (2003) 942-946
41. Witkin J., Tzavara E., Davis R., et al. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends Pharmacol. Sci. 26 (2005) 609-617
42. Zhang P., Ishiguro H., Ohtsuki T., et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol. Psychiatry, 9 (2004) 916-931